# Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Source: https://onco.cc/trials/nct05270044/  
OnCo record `nct05270044` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Encorafenib, Binimetinib in melanoma, run by Pierre Fabre Medicament, active and no longer recruiting.

## Summary

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. is a phase 3 interventional study registered as NCT05270044 by Pierre Fabre Medicament, with 815 participants planned, started 2022-05-02 and due to reach its primary completion in 2027-03-31. Interventions recorded: Encorafenib and Binimetinib, Placebo to match Encorafenib ; Placebo to match Binimetinib. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05270044
- Phase: 3
- Setting: Adjuvant Encorafenib & Binimetinib vs. Placebo in Fully Resected Stage IIB/C BRAF V600E/K Mutated Melanoma: a Randomized Triple-blind Phase III Study in Collaboration With the EORTC Melanoma Group
- Sponsor: Pierre Fabre Medicament
- Enrolled: 815

## Sources

- ClinicalTrials.gov NCT05270044: https://clinicaltrials.gov/study/NCT05270044

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Binimetinib](https://onco.cc/drugs/binimetinib/), [Encorafenib](https://onco.cc/drugs/encorafenib/)

---
JSON: https://onco.cc/api/v1/entities/nct05270044.json